Transmission of HCV infection among long-term hospitalized onco-haematological patients

2003 ◽  
Vol 53 (2) ◽  
pp. 120-123 ◽  
Author(s):  
D Januszkiewicz-Lewandowska ◽  
J Wysocki ◽  
J Rembowska ◽  
M Pernak ◽  
K Lewandowski ◽  
...  
Keyword(s):  
Hcv Infection ◽  
Haematological Patients

scholarly journals Chronic hepatitis C virus infections in Brazilian patients: association with genotypes, clinical parameters and response to long term alpha interferon therapy

1999 ◽  
Vol 41 (3) ◽  
pp. 183-189 ◽  
Author(s):  
Leda BASSIT ◽  
Luiz C. DA SILVA ◽  
Gabriela RIBEIRO-DOS-SANTOS ◽  
Geert MAERTENS ◽  
Flair J. CARRILHO ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hcv Infection ◽  
Sustained Response ◽  
Response To Treatment ◽  
Recombinant Interferon ◽  
Genotype 2

The present study assessed the clinical significance of hepatitis C virus (HCV) genotypes and their influence on response to long term recombinant-interferon-alpha (r-IFN-<FONT FACE="Symbol">a</FONT>) therapy in Brazilian patients. One hundred and thirty samples from patients previously genotyped for the HCV and with histologically confirmed chronic hepatitis C (CH-C) were evaluated for clinical and epidemiological parameters (sex, age, time of HCV infection and transmission routes). No difference in disease activity, sex, age or mode and time of transmission were seen among patients infected with HCV types 1, 2 or 3. One hundred and thirteen of them were treated with 3 million units of r-IFN-<FONT FACE="Symbol">a</FONT>, 3 times a week for 12 months. Initial response (IR) was significantly better in patients with genotype 2 (100%) and 3 (46%) infections than in patients with genotype 1 (29%) (p < 0.005). Among subtypes, difference in IR was observed between 1b and 2 (p < 0.005), and between 1b and 3a (p < 0.05). Sustained response (SR) was observed in 12% for (sub)type 1a, 13% for 1b, 19% for 3a, and 40% for type 2; significant differences were found between 1b and 2 (p < 0.001), and between 1b and 3a (p < 0.05). Moreover, presence of cirrhosis was significantly associated with non response and response with relapse (p < 0.05). In conclusion, non-1 HCV genotype and lack of histological diagnosis of cirrhosis were the only baseline features associated with sustained response to treatment. These data indicate that HCV genotyping may have prognostic relevance in the responsiveness to r-IFN-<FONT FACE="Symbol">a</FONT> therapy in Brazilian patients with chronic HCV infection, as seen in other reports worldwide.

Anti-hepatitis G E2 Antibody Detection and Its Relation to Serum HGV-RNA in Patients with Clotting Disorders: High Prevalence of HGV Infection and Spontaneous Remission

1998 ◽  
Vol 79 (04) ◽  
pp. 752-755 ◽  
Author(s):  
L. Sheng ◽  
A. Soumillion ◽  
K. Peerlinck ◽  
C. Verslype ◽  
R. Schelstraete ◽  
...  
Keyword(s):  
Mononuclear Cells ◽  
Elevated Serum ◽  
Spontaneous Remission ◽  
Normal Serum ◽  
Hcv Infection ◽  
Antibody Detection ◽  
Peripheral Blood Mononuclear ◽  
High Prevalence

SummaryIn a previous study, we have determined the prevalence of serum HGV-RNA in patients with congenital clotting disorders. Twenty-six (15%) of 175 patients investigated were serum HGV-RNA positive. In addition, HGV-RNA was detectable in peripheral blood mononuclear cells (PBMC) in ten percent of the cases, three of these patients were serum HGV-RNA negative.In the present study, we have determined the prevalence of anti-HGV-E2 antibodies in the same patient population. Anti-HGV-E2 as determined by ELISA was detected in 45 patients (25.7%). Forty of these patients were serum HGV-RNA negative.Ninety-two percent of the 26 HGV viremic patients and all but one patient (44 patients) with detectable anti-HGV-E2 had coinfection with the hepatitis C virus (HCV). Of these coinfected patients, 62.5% of HGV viremic patients and 53% of anti-HGV-E2 positive patients showed elevated serum ALT levels. Anti-HGV-E2 seroconversion is thus not associated with HCV infection. Two patients who were solely infected with HGV had normal serum ALT levels. In a retrospective longitudinal study, we have observed in 15 patients that serum HGV-RNA persisted during one to 19 years of follow-up, while anti-HGV-E2 was repeatedly negative. Five additional patients who were anti-HGV-E2 positive with concomitant detectable HGV-RNA (4 patients in serum and 1 patient in PBMC) became HGV-RNA negative during follow-up, ranging from 1 to 8 years after the first detection of anti-HGV-E2 antibodies. Two patients had lost anti-HGV-E2 antibodies 3 to 6 years after the seroconversion without the re-appearance of serum HGV-RNA. From these findings, it is clear that the prevalence rate of HGV infection in patients with clotting disorders as determined by PCR assay for HGV-RNA and anti-HGV-E2 by ELISA is actually higher than the prevalence of HGV viremia. Although HGV viremia may persist for longer than 19 years, most of the patients infected with HGV may clear the viremia spontaneously. The clearance of viremia is usually associated with seroconversion to anti-HGVE2. In addition, anti-HGV-E2 may be lost during years of follow-up without the reappearance of the HGV-RNA. Although HGV infection does not seem to influence the fate of HCV infection and does not induce increased levels of serum ALT, the clinical significance of long-term infection remains to be established.

scholarly journals Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens

2017 ◽  
Vol 38 (5) ◽  
pp. 821-833 ◽  
Author(s):  
K. Rajender Reddy ◽  
Stanislas Pol ◽  
Paul J. Thuluvath ◽  
Hiromitsu Kumada ◽  
Joji Toyota ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Hcv Infection ◽  
Long Term Follow Up ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

P6406Platelet reactivity in Hepatitis C virus infected patients on dual antiplatelet therapy for acute coronary syndrome

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
F Scudiero ◽  
R Valenti ◽  
R Marcucci ◽  
G D Sanna ◽  
A M Gori ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Platelet Reactivity ◽  
Multivariable Analysis ◽  
Hcv Infection ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Coronary Syndrome

Abstract Background Coronary artery disease (CAD) has been recognized as a serious and potentially life-threatening complication of Hepatitis C Virus (HCV) infection. High on treatment platelet reactivity has been associated with high risk of ischemic events in patients with CAD, but data regarding the association with HCV infection are still lacking. Purpose We sought to assess platelet reactivity on dual anti-platelet therapy and long-term outcome of acute coronary syndrome (ACS) patients infected with HCV. Methods ACS patients infected with HCV were matched to ACS patients without HCV for age, sex, diabetes, hypertension and renal function. Primary and secondary study endpoints were the proportion of patients with high on treatment platelet reactivity (HTPR) and long-term outcomes, respectively. Results HCV-infected ACS patients had higher levels of platelet reactivity (ADP10-LTA: 56% ± 18% vs. 44% ± 22%; p=0.002; Arachidonic Acid-LTA: 25% ± 21% vs. 16% ± 15%; p=0.011) and higher rate of HTPR on clopidogrel and aspirin compared with non-HCV patients. Multivariable analysis demonstrated HCV-infection to be an independent predictor of HTPR. At follow-up, estimated major adverse clinical events (MACE: cardiac death, non fatal myocardial infarction and any revascularization) were 57% vs. 37%, p=0.006 in HCV-infected ACS and non-HCV, respectively. Also, TIMI major bleeding rates were higher in HCV-infected subjects (11% vs. 3%; p=0.043) as compared with non-infected patients. Platelet function according to HCV status Conclusions ACS patients with HCV infection have increased on treatment platelet reactivity, higher rate of HTPR, MACE and bleedings as compared with non-HCV patients.

scholarly journals Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity

2015 ◽  
Vol 112 (21) ◽  
pp. 6653-6658 ◽  
Author(s):  
Pavel Skums ◽  
Leonid Bunimovich ◽  
Yury Khudyakov
Keyword(s):  
Immune Escape ◽  
Complex Dynamics ◽  
Viral Evolution ◽  
Hcv Infection ◽  
Viral Population ◽  
Viral Adaptation ◽  
Chronic Hcv Infection ◽  
Potential Strategy ◽  
Chronic Hcv

Hepatitis C virus (HCV) has the propensity to cause chronic infection. Continuous immune escape has been proposed as a mechanism of intrahost viral evolution contributing to HCV persistence. Although the pronounced genetic diversity of intrahost HCV populations supports this hypothesis, recent observations of long-term persistence of individual HCV variants, negative selection increase, and complex dynamics of viral subpopulations during infection as well as broad cross-immunoreactivity (CR) among variants are inconsistent with the immune-escape hypothesis. Here, we present a mathematical model of intrahost viral population dynamics under the condition of a complex CR network (CRN) of viral variants and examine the contribution of CR to establishing persistent HCV infection. The model suggests a mechanism of viral adaptation by antigenic cooperation (AC), with immune responses against one variant protecting other variants. AC reduces the capacity of the host’s immune system to neutralize certain viral variants. CRN structure determines specific roles for each viral variant in host adaptation, with variants eliciting broad-CR antibodies facilitating persistence of other variants immunoreacting with these antibodies. The proposed mechanism is supported by empirical observations of intrahost HCV evolution. Interference with AC is a potential strategy for interruption and prevention of chronic HCV infection.

scholarly journals Long-Term Effect on Natural Killer Cells by Interferon-α Therapy on the Outcomes of HCV Infection

2014 ◽  
Vol 34 (5) ◽  
pp. 366-375 ◽  
Author(s):  
Xiaoli Hu ◽  
Yanfang Jiang ◽  
Xiurong Li ◽  
Yanhang Gao ◽  
Xiaoli Guo ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Term Effect ◽  
Hcv Infection ◽  
Interferon Α ◽  
Killer Cells ◽  
Long Term Effect
Sign in / Sign up

Export Citation Format

Share Document